552 related articles for article (PubMed ID: 30075736)
1. Combined pretreatment with
Ji S; Hu Q; Zhu J; Chen J; Chen Q; Liu Z; Shen C; Yang R; Sun H; Wu J; Gu K
Trials; 2018 Aug; 19(1):416. PubMed ID: 30075736
[TBL] [Abstract][Full Text] [Related]
2. Patterns of failure after use of (18)F-FDG PET/CT in integration of extended-field chemo-IMRT and 3D-brachytherapy plannings for advanced cervical cancers with extensive lymph node metastases.
Chung YL; Horng CF; Lee PI; Chen FL
BMC Cancer; 2016 Mar; 16():179. PubMed ID: 26940959
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the prognostic value of F-18 FDG PET/CT metabolic parameters of primary tumors and MRI findings in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy.
Dag Z; Yilmaz B; Dogan AK; Aksan DU; Ozkurt H; Kızılkaya HO; Arslan D
Brachytherapy; 2019; 18(2):154-162. PubMed ID: 30594422
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of FIGO staging defined by combining MRI and [
Raffa S; Lanfranchi F; Satragno C; Giannelli F; Marcenaro M; Coco A; Cena SE; Sofia L; Marini C; Mammoliti S; Levaggi A; Tagliafico AS; Sambuceti G; Barra S; Morbelli S; Belgioia L; Bauckneht M
Curr Probl Cancer; 2023 Dec; 47(6):101007. PubMed ID: 37684197
[TBL] [Abstract][Full Text] [Related]
5. Changes on Midchemoradiation Therapy Fluorodeoxyglucose Positron Emission Tomography for Cervical Cancer Are Associated with Prognosis.
Carpenter DJ; Jacobs CD; Wong TZ; Craciunescu O; Chino JP
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):356-366. PubMed ID: 31254659
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule.
Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K;
Gynecol Oncol; 2012 Aug; 126(2):211-6. PubMed ID: 22555110
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography for staging locally advanced cervical cancer and assessing intensity modulated radiotherapy approach.
Draghini L; Costantini S; Vicenzi L; Italiani M; Loreti F; Trippa F; Arcidiacono F; Casale M; Mantello G; Maranzano E
Radiol Med; 2019 Sep; 124(9):819-825. PubMed ID: 30904982
[TBL] [Abstract][Full Text] [Related]
8. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
Chen CC; Wang L; Lin JC; Jan JS
J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
[TBL] [Abstract][Full Text] [Related]
9. Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG1066).
Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K;
Int J Gynecol Cancer; 2012 Oct; 22(8):1420-6. PubMed ID: 22932262
[TBL] [Abstract][Full Text] [Related]
10. Split-field helical tomotherapy with or without chemotherapy for definitive treatment of cervical cancer.
Chang AJ; Richardson S; Grigsby PW; Schwarz JK
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):263-9. PubMed ID: 21167656
[TBL] [Abstract][Full Text] [Related]
11. (
Scher N; Castelli J; Depeursinge A; Bourhis J; Prior JO; Herrera FG; Ozsahin M
Cancer Radiother; 2018 May; 22(3):229-235. PubMed ID: 29650390
[TBL] [Abstract][Full Text] [Related]
12. Feasibility study of toxicity outcomes using GEC-ESTRO contouring guidelines on CT based instead of MRI-based planning in locally advanced cervical cancer patients.
Koh V; Choo BA; Lee KM; Tan TH; Low JH; Ng SY; Ilancheran A; Shen L; Tang J
Brachytherapy; 2017; 16(1):126-132. PubMed ID: 27816539
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced cervical cancer.
Kidd EA; Siegel BA; Dehdashti F; Rader JS; Mutic S; Mutch DG; Powell MA; Grigsby PW
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1085-91. PubMed ID: 19880262
[TBL] [Abstract][Full Text] [Related]
14. A Randomized Controlled Trial Comparing Clinical Outcomes and Toxicity of Lobaplatin- Versus Cisplatin-Based Concurrent Chemotherapy Plus Radiotherapy and High-Dose-Rate Brachytherapy for FIGO Stage II and III Cervical Cancer.
Wang JQ; Wang T; Shi F; Yang YY; Su J; Chai YL; Liu Z
Asian Pac J Cancer Prev; 2015; 16(14):5957-61. PubMed ID: 26320479
[TBL] [Abstract][Full Text] [Related]
15. False negative rate at
Gouy S; Seebacher V; Chargari C; Terroir M; Grimaldi S; Ilenko A; Maulard A; Genestie C; Leary A; Pautier P; Morice P; Deandreis D
BMC Cancer; 2021 Feb; 21(1):135. PubMed ID: 33549033
[TBL] [Abstract][Full Text] [Related]
16. Pre-treatment prediction of early response to chemoradiotherapy by quantitative analysis of baseline staging FDG-PET/CT and MRI in locally advanced cervical cancer.
Min LA; Ackermans LL; Nowee ME; Griethuysen JJV; Roberti S; Maas M; Vogel WV; Beets-Tan RG; Lambregts DM
Acta Radiol; 2021 Jul; 62(7):940-948. PubMed ID: 32722967
[TBL] [Abstract][Full Text] [Related]
17. Dose escalated intensity modulated radiotherapy in the treatment of cervical cancer.
Cihoric N; Tsikkinis A; Tapia C; Aebersold DM; Zlobec I; Lössl K
Radiat Oncol; 2015 Nov; 10():240. PubMed ID: 26597282
[TBL] [Abstract][Full Text] [Related]
18. The Role of Pretreatment FDG-PET in Treating Cervical Cancer Patients With Enlarged Pelvic Lymph Node(s) Shown on MRI: A Phase 3 Randomized Trial With Long-Term Follow-Up.
Lin SY; Tsai CS; Chang YC; Ng KK; Chang TC; Kao WH; Lai CH; Hong JH
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(3):577-85. PubMed ID: 25936817
[TBL] [Abstract][Full Text] [Related]
19. [
Adam JA; Poel E; van Eck Smit BLF; Mom CH; Stalpers LJA; Laan JJ; Kidd E; Stoker J; Bipat S
BMC Cancer; 2024 Apr; 24(1):513. PubMed ID: 38654241
[TBL] [Abstract][Full Text] [Related]
20. Prospective study of functional bone marrow-sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignancies.
Liang Y; Bydder M; Yashar CM; Rose BS; Cornell M; Hoh CK; Lawson JD; Einck J; Saenz C; Fanta P; Mundt AJ; Bydder GM; Mell LK
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):406-14. PubMed ID: 22687195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
